Fuji opens 62,000-sq-ft facility in Research Triangle Park, NC

Fuji
Fujifilm Diosynth Biotechnologies North Carolina facility

Fujifilm Diosynth Biotechnologies is less than 5 years old as CMO for biopharmaceuticals but has quickly built up its infrastructure. This week it added another operation to its stable.

The Japanese-based company officially opened a 62,000-square-foot facility in Research Triangle Park, NC, to house its process and analytical research and development, process sciences and stability groups. The BioProcess Innovation Center not only is adding services but also intends to develop more efficient biologics manufacturing processes, the company said.

“The design of the facility reflects our core philosophy of cross-functional collaboration to research and process development,” Martin Meeson, president of Fujifilm Diosynth Biotechnologies U.S.A., said in a statement.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Fujifilm jumped into biologics manufacturing in 2011 when it reportedly paid about $490 million to buy biologics plants in North Carolina and Northeast England from Merck & Co. ($MRK), when the U.S. company decided it wanted out of the contract business.

Fujifilm expanded the facility in the U.K. in 2013 and then in 2014 bought a 49% interest in vaccine specialist Kalon Biotherapeutics, which is working with GlaxoSmithKline ($GSK) on a government-backed vaccine plant in Texas. GSK is building the $91 million, 100,000-square-foot Pandemic Influenza Vaccine Facility with the university. The facility, which has gotten U.S. federal funds, will be available to the government in the case of a pandemic. 

- here’s the announcement 

Related Articles: 
Fujifilm expands former Merck biologics plant in U.K. 
Fujifilm adding Texas-based vaccine specialist to its fold

Read more on

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.